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Background: Globally, rheumatic heart disease (RHD) remains an important cause of heart disease. In Australia it
particularly affects older non-Indigenous Australians and Aboriginal Australians and/or Torres Strait Islander peoples.
Factors associated with the choice of treatment for advanced RHD remain variable and poorly understood.
Methods: The Australian and New Zealand Society of Cardiac and Thoracic Surgeons Cardiac Surgery Database was
analysed. Demographics, co-morbidities, pre-operative status and valve(s) affected were collated and associations
with management assessed.
Results: Surgical management of 1384 RHD and 15843 non-RHD valve procedures was analysed. RHD patients
were younger, more likely to be female and Indigenous Australian, to have atrial fibrillation (AF) and previous
percutaneous balloon valvuloplasty (PBV). Surgery was performed on one valve in 64.5%, two valves in 30.0% and
three valves in 5.5%. Factors associated with receipt of mechanical valves in RHD were AF (OR 2.69) and previous
PBV (OR 1.98) and valve surgery (OR 3.12). Predictors of valve repair included being Indigenous (OR 3.84) and having
fewer valves requiring surgery (OR 0.10). Overall there was a significant increase in the use of mitral bioprosthetic
valves over time.
Conclusions: RHD valve surgery is more common in young, female and Indigenous patients. The use of
bioprosthetic valves in RHD is increasing. Given many patients are female and younger, the choice of valve surgery
and need for anticoagulation has implications for future management of RHD and related morbidity, pregnancy
and lifestyle plans.
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Rheumatic heart disease (RHD) is a condition of global
health importance. It is estimated 15.6 - 19.6 million
people are living with RHD, with almost 80% of those
residing in low and middle-income countries [1,2].
Whilst RHD is now rare in high income countries [3], it
remains an important cause of preventable heart disease
in some Indigenous populations in these countries. This
is likely to be explained by a combination of educational,
economic and environmental disadvantage and reduced
access to primary and specialist health care [4]. In 2010
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unless otherwise stated.and Torres Strait Islander Indigenous peoples was 6.45 per
1000 or 26 times that of non-Indigenous Australians [5]. A
recent echocardiographic screening study of Indigenous
Australian children aged 5–14 years, found a prevalence of
definite RHD [6] of 8.6 per 1000 (95% CI 6.0-12.0) with
none detected in a comparably aged non-Indigenous
cohort [7].
In some populations at risk of RHD, such as Aboriginal
Australians and Torres Strait Islanders, outcomes follo-
wing cardiac surgery can be inferior [8,9] despite being of
younger age at time of surgery [8]. This is likely to be re-
lated to factors including comorbidities [4,8,9], barriers to
primary and specialist health care and the ability to achieve
safe anticoagulation during long-term follow-up [10].
The most common heart valves affected by RHD and
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Rheumatic valve disease most commonly leads to re-
gurgitation [6,11] and less commonly to valve stenosis
or mixed regurgitation and stenosis [12]. Although the
majority of rheumatic valve disease cases are only mildly
affected, [1] a minority progress to more severe disease
requiring valve surgery [13].
The options for surgical management of rheumatic
valve disease are valve repair or replacement with either
a bioprosthetic or mechanical prosthesis. In patients
with mitral stenosis an additional option is non-surgical
percutaneous mitral balloon valvuloplasty [12,14]. There
are limited data available about factors which might
affect the choice of surgery in patients with rheumatic
valve disease. This decision is likely to be influenced by
patient geography, medication access and use, timing
and venue of referral, gender and access to ongoing care
and follow-up. There have been no Australian multi-
centre studies of rheumatic valve surgery published with
most published data pertaining to small single centre
series.
The aim of this study was thus to examine the Australian
patient population having valve surgery for RHD and re-
view the pre-operative factors associated with the choice of
surgical management of RHD in Australia.
Methods
The database
The Australia and New Zealand Society of Cardiac and
Thoracic Surgeons (ANZSCTS) National Cardiac Surgery
Database is an Australia-wide database for the collection
and analysis of cardiac surgical procedures, established to
enable benchmarking and comparison with international
standards [15]. The database definition set was developed
by the ANZSCTS for all participating cardiac surgery
units. There is an opt-out Patient Information Sheet which
has the approval of each site’s Human Research Ethics
Committee. At present 19 of 25 Australian public hospital
cardiac surgical units enter data relating to cardiac
surgical procedures that identify whether patients are
Aboriginal Australians and/or Torres Strait Islanders.
The database collects patient demographics, co-
morbidities, pre-operative status, previous interventions,
haemodynamic data, surgery type and surgical and post-
operative outcome data. Only de-identified data is ab-
stracted and utilised for analysis.
Analysis
The aim of the analysis was to describe patients having
valve surgery for rheumatic valve disease, to compare
Aboriginal and Torres Strait Islander RHD patients with
non-Indigenous Australians and to describe and identify
factors associated with treatment choice. Demographic
data included age, gender, Indigenous status, concomitantcoronary artery bypass grafting (CABG) and rurality by Re-
moteness Area (RA) category as defined by the Australian
Statistical Geography Standard [16]. Co-morbidities as-
sessed included chronic kidney disease (defined as pre-
operative estimated glomerular filtration rate (eGFR) less
than 60 mL/min/1.73 m2 based on the Modification of
Diet in Renal Disease (MDRD) equation and stratified to
stages 3 (30 - 59 mL/min/1.73 m2), 4 (15 - 29 mL/min/
1.73 m2), and 5 (<15 mL/min/1.73 m2) [17], elevated
(200 μmol/L or more) pre-surgery serum creatinine, a pre-
existing clinician diagnosis of diabetes mellitus and hyper-
tension and smoking status.
The pre-operative status relating to underlying heart dis-
ease included symptomatic status based on the New York
Heart Association (NYHA) classes I to IV [18], pre-
operative atrial fibrillation, echocardiographic assessment
of left ventricular ejection fraction (LVEF) (stratified to
more than 45%, 30% - 45% and less than 30%), previous
valve surgery and percutaneous balloon valvuloplasty
(PBV). Valvular lesions were analysed according to the
valve(s) affected, the valvular lesion (regurgitation, stenosis
or mixed), the number of valves affected, and the year of
surgery. Valve-related surgical procedure data included
valve repair or replacement and in the case of replace-
ment, whether this was a mechanical or bioprosthetic
valve.
Statistical analysis
Data were analysed using IBM SPSS Statistics 20 (IBM,
New York, USA) and Stata 13 (StataCorp LP, Texas, USA).
Descriptive data were summarised using standard univa-
riate techniques and reported as percentages with 95%
confidence intervals (95% CI), means with standard de-
viation (SD) or medians with interquartile range (IQR) de-
pending on the data format and distribution. Comparisons
between groups were undertaken using χ2 for categorical
data and Student’s t-Test or Mann–Whitney U test for con-
tinuous Normally distributed or non-Normally distributed
data respectively. A p valve less than 0.05 was taken to indi-
cate statistical significance and all tests were two-sided.
Logistic regression models were developed to identify
independent factors associated with the type of valve sur-
gical procedure utilised. These were developed using a
backwards stepwise approach including in the first model
all factors associated with a particular management choice
using bivariate analysis with a p value <0.1. Factors with a
p value > =0.05 were progressively removed from the
models starting with the variable with an odds ratio (OR)
closest to 1. Interactions between predictive factors were
explored and final models were limited to predictive fac-
tors with significant coefficients (p < 0.05).
Approval for this project was granted by the Monash
University Human Research Ethics Committee (CF13/
2737 – 2013001472).
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Data in relation to 62 707 cardiac surgical procedures
performed between 1 August 2001 and 31 December
2012 were analysed. A breakdown of those procedures is
summarized in Figure 1.
A subset of 17 227 surgical valve procedures with or
without coronary artery bypass grafting (CABG) was in-
cluded for analysis. Contributing surgical centres have
increased from five in 2001 with 33 RHD valve surgeries
to 26 in 2012 and 203 RHD valve surgeries (Figure 2).
Descriptive characteristics of these valve surgery pa-
tients are outlined in Table 1. RHD valve surgery pa-
tients were, compared with non-RHD valve surgery
patients, younger, more likely to be female and Aboriginal
and/or Torres Strait Islander and were less likely to
have concomitant CABG, severely impaired left ven-
tricular systolic function (LVEF <30%) or associated
diabetes or hypertension. RHD patients were also more
likely to have associated atrial fibrillation (AF), be
current smokers or have a past history of valve surgery
and/or PBV.
In multivariate modeling, patients undergoing RHD-
related surgery were younger (OR 0.99/additional year,
95% CI 0.97 – 1.00), more likely to be female (OR 4.15,
95% CI 3.00 – 5.75), Aboriginal and/or Torres Strait
Islander (OR 5.10, 95% CI 2.67 – 9.80), have associated
AF (OR 3.85, 95% CI 2.72 – 5.44), a history of PBV (OR
5.71, 95% CI 3.37 – 9.71) or prior valve surgery (ORFigure 1 Cardiac surgical procedures collected in the ANZCTS Databa1.81, 95% CI 1.26 – 2.60), and were less likely to have
hypertension (OR 0.67, 95% CI 0.46 – 1.00) or severe left
ventricular dysfunction (OR 0.17, 95% CI 0.05 – 0.58).
Details regarding RHD valve surgery patients, stratified by
Indigenous status, are outlined in Table 2. In biva-
riate analyses Aboriginal Australian and/or Torres Strait
Islander RHD valve surgery patients were, compared with
non- Indigenous Australian patients, younger and less
likely to have concomitant CABG, associated chronic
kidney disease, hypertension or AF. They were also more
likely to be previous or current smokers and to be living
in remote Australia. In multivariate logistic regression
modeling, Indigenous Australian patients were younger
(OR 0.89/additional year, 95% CI 0.87 – 0.91), current
smokers (OR 2.52, 95% CI 1.40 – 4.51), residents of re-
mote Australia (OR 15.39, 95% CI 7.81 – 30.30) and, in
contrast to bivariate analysis, were more likely to have as-
sociated hypertension (OR 1.87, 95% CI 1.04 – 3.39),
chronic kidney disease (OR 2.22, 95% CI 1.07 – 4.59) and
AF (OR 2.09, 95% CI 1.17 – 3.71) once age was controlled
for. There were no significant independent interactions
between these factors.
Of patients having RHD valve surgery, 64.5% (95% CI
61.91 – 67.02) required surgery on one valve only, 30.0%
(95% CI 27.60 – 32.50) on two valves and 5.5% (95% CI
4.35 – 6.83) on three valves. The details of the valves
involved and the associations between different valvular
involvement is outlined in Table 3. RHD pulmonary valvese between 1 August 2001 and 31 December 2012.
Figure 2 Number of contributing surgical centres and RHD valve procedures over time.
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0.60) of procedures and combined RHD aortic, mitral and
pulmonary valve surgery, 0.1% (95% CI: 0.02 – 0.52).
The choice of surgical valve procedure for aortic,
mitral and tricuspid valve disease overall and stratified
by Indigenous status is outlined in Table 4. In bivariate
analyses, Indigenous patients were less likely to have
mechanical mitral valve replacement, more likely to have
mitral valve repair and less likely to have bioprosthetic
aortic valve replacement.
Multivariate logistic regression modeling was under-
taken to identify independent predictors of mechanical
versus bioprosthetic valve replacement and valve replace-
ment versus repair. In patients having an RHD-related
valve replacement, mechanical valves, compared with only
using bioprosthetic valves, were more likely to be used in
those with associated AF (OR 2.69, 95% CI 1.64 – 4.43),
when more than one valve required surgery (OR 1.61 for
each additional valve, 95% CI 1.03 – 2.49) and if there was
a history of previous PBV (OR 3.12, 95% CI 1.87 – 5.21)
or other valve surgery (OR 3.12, 95% CI 1.87 – 5.21).
Mechanical valves were less likely to be used in those with
diabetes (OR 0.51, 95% CI 0.29 – 0.89) or chronic kidney
disease (OR 0.50, 95% CI 0.30 – 0.83). Whilst the median
age of those receiving mechanical valves was significantly
lower (57.1 years, IQR (50.0 – 67.1)) than for those re-
ceiving bioprosthetic valves (65.8 years, (61.2 – 77.0),
p = <0.001), this was not significant after adjusting for
these other covariates. Indigenous status and remoteness
of residence were not significant predictors of valve type
choice.
In multivariate modelling, patients having isolated
valve repair, compared with any valve replacement, were
more likely to be Aboriginal and Torres Strait Islander
(OR 5.50, 95% CI 3.24 – 9.35), to have fewer valves re-
quiring surgery (OR 0.10 for each additional valve, 95%
CI 0.04 – 0.28) and were less likely to have hypertension
(OR 0.53, 95% CI 0.32 – 0.89) or a history of smoking(OR 0.59, 95% CI 0.37 – 0.96). Whilst patients having
isolated valve repair, compared with any valve replace-
ment were more likely to be younger, reside in a remote
area and less likely to have associated AF or concomitant
CABG, these were not significant predictors after adjus-
ting for other significant covariates.
Temporal trends in the surgical management of RHD-
related mitral and aortic valve disease are outlined in
Figures 3 and 4. Overall there was no significant change in
aortic valve surgery type over this time. Mitral valve pro-
cedures demonstrated a significant increase in biopros-
thetic valve replacements (1.8% increase as a proportion
of all mitral valve procedures/year, 95% CI 1.0 – 2.6) and a
corresponding fall in mechanical valve replacements (1.8%
decrease/year, 95% CI 1.0 – 2.6). Whilst mitral valve
repairs decreased (1.0% decrease/year, 95% CI −0.5 – 1.7)
this was not statistically significant. Given major centres
undertaking valve surgery for Aboriginal and Torres Strait
Islander peoples only began submitting data from 2006,
analysis of temporal trends in the choice of valve surgery
stratified by Indigenous status was restricted to 2006 –
2012. Analysis of mitral procedures over time revealed
mitral valve repairs declined (Spearman rank r = −0.786,
p = 0.036) in Aboriginal and Torres Strait Islander pa-
tients from 2006–2012. Aortic valve procedures in non-
Indigenous Australian patients over the same time
demonstrated an increase in the use of bioprosthetic
valves (Spearman rank r = 0.857, p = 0.014) and a de-
crease in mechanical valves (Spearman rank r = −0.929,
p = 0.003). The surgical management of mitral valve
disease in non-Indigenous Australians and aortic valve
disease in Aboriginal and Torres Strait Islander peoples
did not alter significantly over this time.
The nature of the underlying RHD-related mitral and
aortic valve lesions stratified by Indigenous status
are outlined in Table 5. Aboriginal and Tosses Strait
Islander people were, compared with non-Indigenous
Australians, more likely to have only mitral stenosis and
Table 1 Descriptive characteristics of valve surgery patients stratified by causation
All RHD-related Non-RHD P value
N = 17227 N = 1384 N = 15843
Age (years) 71.3 59.7 71.9 <0.001
(Median (IQR)) (61.2 – 78.3) (50.9 – 71.4) (62.3 – 78.6)
Sex (% female) 37.3 64.5 35.0 <0.001
(95% CI) (36.6 – 38.1) (61.9 – 67.0) (34.2 – 35.7)
Indigenous status 1.9 12.6 1.0 <0.001
(% Aboriginal and Torres Strait Islander people) (95% CI) (1.7 – 2.1) (10.9 – 14.4) (0.8 – 1.2)
Concomitant CABG 39.1 21.2 40.7 <0.001
(%, 95% CI) (38.4 – 39.8) (19.1 – 23.5) (39.9 – 41.4)
Pre-operative comorbidities
Diabetes 23.2 20.3 23.4 0.009
(%, 95% CI) (22.5 – 23.8) (18.2 – 22.5) (22.8 – 24.1)
Elevated Creatinine 3.4 2.8 3.5 0.436
(% Cr > =200 μmol/L, 95% CI) (3.1 – 3.7) (2.0 – 03.8) (3.2 – 03.8)
Chronic kidney disease 36.7 31.2 37.2 0.814
(% eGFR < 60 mL/min/1.73 m2) (95% CI) (36.0 – 37.5) (28.8 – 33.7) (36.5 – 38.0)
Hypertension 67.0 53.0 68.2 <0.001
(%, 95% CI) (66.3 – 67.7) (50.3 – 55.7) (67.5 – 68.9)
Previous smoking 53.1 52.7 53.1 0.955
(%, 95% CI) (52.3 -53.8) (50.0 - 55.3) (52.3 - 53.9)
Current smoking 16.0 25.1 15.2 <0.001
(%, 95% CI) (15.2 - 16.7) (22.0 - 28.4) (14.5 - 16.0)
Pre-operative status
NYHA classes III & IV 43.7 53.7 42.8 0.351
(%, 95% CI) (42.9 – 44.4) (51.0 – 56.4) (42.0 – 43.6)
Atrial fibrillation 19.3 40.5 17.4 <0.001
(%, 95% CI) (18.7 – 19.9) (37.9 – 43.2) (16.8 – 18.0)
LVEF >45% 81.2 84.6 80.9 0.001
(%, 95% CI) (80.6 – 81.8) (82.6 – 86.5) (80.3 – 81.5)
LVEF 45 – 60% 12.1 10.9 12.2 0.154
(%, 95% CI) (11.6 – 12.6) (9.3 – 12.7) (11.7 – 12.7)
LVEF <30% 4.3 2.2 4.5 <0.001
(%, 95% CI) (4.0 – 4.6) (1.5 – 3.2) (4.2 – 4.8)
Previous procedures
Valve surgery 6.4 13.5 5.8 <0.001
(%, 95% CI) (6.1 – 6.8) (11.8 – 15.4) (5.4 – 6.2)
PBV 4.9 20.7 3.3 <0.001
(%, 95% CI) (4.3 – 5.6) (16.7 – 25.2) (2.8 – 4.0)
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more likely to have isolated aortic regurgitation, were
less likely to have aortic stenosis only or mixed aortic
disease.The utilisation of mitral or aortic valve repair as com-
pared with valve replacement stratified by the underlying
valve lesion is presented in Table 6. Mitral valve repair
was more likely to be undertaken in isolated regurgitation
Table 2 Descriptive characteristics of RHD valve surgery patients stratified by Indigenous status
Aboriginal and/or Torres Strait Islander Non-Indigenous Australian P value
N = 174 N = 1210
Age (years) 37.4 65.1 <0.001
(Median (IQR)) (26.9 – 49.1) (55.5 – 72.8)
Sex (% female) 67.2 64.0 0.411
(95% CI) (59.7 – 74.2) (61.3 – 66.8)
Concomitant CABG 9.8 22.9 <0.001
(%, 95% CI) (5.8 – 15.2) (20.6 – 25.4)
Area of residence
Remote and very remote 54.1 1.6 <0.001
(% RA category 3 & 4, 95% CI) (46.3 – 61.7) (1.0 – 2.4)
Inner and outer regional 39.5 33.3 0.108
(% RA category 1 & 2, 95% CI) (32.2 – 47.3) (30.7 – 36.1)
Major city 6.4 65.1 <0.001
(%, 95% CI) (3.2 – 11.2) (62.3 – 67.8)
Pre-surgery comorbidities
Diabetes 24.3 19.8 0.167
(%, 95% CI) (18.1 – 31.4) (17.5 – 22.1)
Elevated Creatinine 2.9 2.7 0.912
(% Cr > =200 μmol/L) (95% CI) (0.9 – 6.6) (1.9 – 3.8)
Chronic kidney disease (% eGFR < 60 mL/min/1.73 m2) 14.4 33.5 <0.001
(95% CI) (9.5 – 20.5) (30.8 – 36.2)
Hypertension 37.0 55.3 <0.001
(%, 95% CI) (29.8 – 44.7) (52.4 – 58.1)
Previous smoking 64.2 51.0 <0.001
(%, 95% CI) (56.5 – 71.3) (48.2 – 53.9)
Current smoking 55.4 19.7 <0.001
(%, 95% CI) (45.7 – 64.8) (16.7 – 23.1)
Pre-operative status
NYHA classes III & IV 47.1 53.1 0.138
(%, 95% CI) (39.5 – 54.8) (50.3 – 56.0)
Atrial fibrillation 33.3 41.6 0.039
(%, 95% CI) (26.4 – 40.9) (38.8 – 44.4)
LVEF >45% 83.9 84.7 0.784
(%, 95% CI) (77.6 – 89.0) (82.6 – 86.7)
LVEF 30 – 45% 11.5 10.8 0.792
(%, 95% CI) (7.2 – 17.2) (9.1 – 12.7)
LVEF <30% 3.4 2.1 0.249
(%, 95% CI) (1.3 – 7.4) (1.3 – 3.1)
Previous procedures
Valve surgery 16.1 13.1 0.287
(%, 95% CI) (11.0 – 22.4) (11.3 – 15.2)
PBV 29.5 19.5 0.124
(%, 95% CI) (16.8 – 45.2) (15.3 – 24.3)
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Table 3 Association between different RHD-related valve
disease requiring surgical management
% (95% CI)
1 valve
Mitral valve only 40.3 (37.7 – 42.9)
Aortic valve only 22.9 (20.7 – 25.2)
Tricuspid valve only 1.2 (0.7 – 2.0)
2 valves
Mitral and aortic valves 20.6 (18.5 – 22.8)
Mitral and tricuspid valves 8.5 (7.1 – 10.1)
Aortic and tricuspid valves 0.7 (0.3 – 1.3)
3 valves
Mitral, aortic and tricuspid valves 5.4 (4.2 – 6.7)
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mixed disease.
Discussion
This study is the first to provide a detailed description of
Australian RHD valve surgery. It analysed 17227 patients
in Australia who had surgical valve procedures per-
formed between 2001 and 2012 including 1384 RHDTable 4 Surgical management of RHD valve disease stratified
procedures performed; all on non-Indigenous patients)
% (95% CI) Total RHD Aboriginal and/or Torre
N = 1384 N = 174
Mitral N = 153
Mechanical valve 65.5 51.6
(62.5 – 68.4) (43.4 – 59.
Bioprosthetic valve 24.5 26.8
(21.9 – 27.3) (20.0 – 34.
Valve Repair 10 21.6
(6.4 – 14.8) (15.3 – 28.
Aortic N = 62
Mechanical valve 53.6 64.5
(49.8 – 57. 4) (51.3 – 76.
Bioprosthetic valve 44.2 32.3
(40.5 – 48.0) (20.9 – 45.
Valve Repair 2.2 3.2
(1.22 – 3.56) (0.4 – 11.2
Tricuspid N = 31
Mechanical valve 10 3.2
(8.2 – 11.9) (0.1 – 16.7
Bioprosthetic valve 3.7 6.5
(1.6 – 7.1) (0.8 – 21.4
Valve Repair 86.3 90.3
(81.0 – 90.6) (74.2 – 98.valve procedures. The high burden of RHD among
Aboriginal and Torres Strait Islander people was reflected
in the relatively high percentage of Indigenous Australians
requiring RHD surgery (12.6%) compared with their rep-
resentation in the overall Australian population (2.5%)
[19]. Advanced RHD affects people at a younger age
compared with non-RHD-related valve disease [20,21].
Australians in general and Aboriginal Australian and/or
Torres Strait Islander in particular required RHD valve
surgery at a younger age, a finding reflected in several
earlier studies [9,22].
The finding that RHD surgery patients were both
younger and more likely to be female has implications
for treatment choice, particularly given the potential
hazards of anticoagulation associated with future preg-
nancies [23]. It is also of relevance for other younger
people who often participate in activities associated with
an increased risk of trauma (e.g. contact sports). AF was
more common in those having RHD-related compared
to non-RHD-related valve surgery. Undertaking RHD
mitral valve surgery prior to the onset of AF would
appear to provide greater therapeutic choice as both
bioprosthetic valve replacement and valve repair do not
typically require ongoing anticoagulation in the presenceby Indigenous status (There were only five pulmonary




8) (64.7 – 71.0)
24.1 0.482
5) (21.4 – 27.1)
7.9 <0.001
9) (6.2 – 9.9)
N = 628
52.5 0.071
3) (48.6 – 56.5)
45.4 0.047
3) (41.4 – 49.4)
2.1 0.552
) (1.1 – 3.5)
N = 188
11.2 0.173
) (7.0 – 16.6)
3.2 0.370
) (1.2 – 6.8)
85.6 0.482
0) (79.8 – 90.3)
Figure 3 Changes in RHD mitral valve surgery over time, total and stratified by Indigenous status. (Numbers at the top of each column
refer to the total number of procedures for that year).
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ticularly useful when managing younger and female pa-
tients for the reasons outlined above and for Indigenous
Australian patients who are more likely to reside in re-
mote communities where anticoagulation monitoring and
ongoing specialist review can be difficult. Nonetheless the
associated increased risk of surgical re-operation in valve
repair and bioprosthetic valve replacement must also be
considered in the decision-making process.
There was an independent association between RHD
valve surgery and previous PBV for mitral stenosis. This is
not surprising given PBV can often provide temporary re-
lief of mitral stenosis with restenosis being reported in a
number of studies, ranging from 40% of patients at six
years [24], 34% at 10 years [25] and 21% at 15 years
[26,27]. Despite this risk of restenosis, PBV can provide a
non-invasive approach to mitral stenosis management that
does not necessarily require ongoing anticoagulation and
which has excellent overall survival rates ranging from
96.5% at three years [24] to 99.2% at 16 years [26].
Aboriginal Australian and/or Torres Strait Islander
people were less likely to have concomitant CABG when
having RHD-related valve surgery. This is surprising
given Indigenous Australians are hospitalised 1.9 times
more than non-Indigenous Australians for coronaryheart disease [28]. Nonetheless this may, at least in
part, be explained by the younger age of Indigenous
Australian RHD patients who had a median age nearly
30 years less than that of non-Indigenous patients.
We also found Indigenous Australian RHD patients
were less likely to have associated kidney disease. This is
also perhaps unexpected given the well-documented epi-
demic of kidney disease in Aboriginal and Torres Strait
Islander people [29]. Nonetheless this finding did not
persist in multivariate analysis, suggesting the older age
of non-Indigenous Australian RHD patients had a grea-
ter effect on chronic kidney disease risk compared with
younger Aboriginal and Torres Strait Islander patients.
This finding is not universal and Indigenous Australian
cardiac surgical patients have reported to have an in-
creased burden of kidney disease pre-operatively [7,8].
These reports are likely to have represented Aboriginal
and Torres Strait Islander populations which may have
been at greater risk of chronic kidney disease due to the
high proportion of patients residing in remote centres
where the risk of kidney disease has also been shown to
be greater [29,30]. Such disparity between these earlier
single centre studies and our larger multicenter review
reinforces the benefits of national data collection sys-
tems such as that used here.
Figure 4 Changes in RHD aortic valve surgery over time, total and stratified by Indigenous status. (Numbers in each column refer to the
total valve surgeries for that year).
Table 5 RHD Mitral and aortic valve lesions types stratified by Indigenous status
% (95% CI) Total RHD Aboriginal and/or Torres Strait Islander Non-Indigenous Australian P value
N = 1384 N = 174 N = 1210
Mitral n = 152 n = 882
Stenosis only 5.3 12.1 4.3 <0.001
(95% CI) (4.2 – 6.6) (7.6 – 17.9) (3.2 – 5.6)
Regurgitation only 21 31.0 19.5 <0.001
(95% CI) (18.8 – 23.2) (24.3 – 38.5) (17.3 – 21.9)
Combined regurgitation and stenosis 28.8 36.2 27.8 0.022
(95% CI) (26.5 – 31.3) (29.1 – 43.8) (25.3 – 30.4)
Aortic valve n = 62 n = 628
Stenosis only 4.9 1.1 5.5 0.014
(95% CI) (3.8 – 6.2) (0.1 – 4.1) (4.2 – 6.9)
Regurgitation only 12.1 21.8 10.7 <0.001
(95% CI) (10.4 – 13.9) (15.9 – 28.7) (9.0 – 12.5)
Combined regurgitation and stenosis 17.1 12.1 17.8 0.052
(95% CI) (15.1 – 19.1) (7.6 – 17.9) (15.7 – 20.0)
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Table 6 RHD Mitral and aortic valve lesions types stratified by isolated repair or replacement
% all valve procedures (95% CI) Isolated valve repair N = 74 Any valve replacement N = 1297 P value repair versus replacements
Mitral
Stenosis only 6.8 5.2 0.573
(95% CI) (2.2 – 15.1) (4.1 – 6.6)
Regurgitation only 54.1 19.0 <0.001
(95% CI) (42.165.7) (16.9 – 21.2)
Combined regurgitation and stenosis 14.9 29.8 0.006
(95% CI) (7.7 – 25.0) (27.3 – 32.3)
Aortic valve
Stenosis only 1.4 5.2 0.142
(95% CI) (0.03 – 7.3) (04.0 – 6.5)
Regurgitation only 9.5 12.3 0.462
(95% CI) (3.9 – 18.5) (10.6 – 14.3)
Combined regurgitation and stenosis 5.4 17.8 0.006
(95% CI) (1.5 – 13.3) (15.7 – 20.0)
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with earlier studies, most commonly the mitral and aortic
valves, less commonly the tricuspid and rarely the pul-
monary valve. Isolated RHD-related tricuspid valve disease
is relatively uncommon [31] and represented only 1.2% of
Australian patients having RHD valve surgery. Thirty
percent of patients having RHD-related surgery required
management of multiple valves, highlighting the increased
complexity of surgery in RHD-related valve disease.
The choice of valve procedure is likely to be informed
by a combination of patient, health practitioner choice,
demographic and disease factors. A mechanical valve
has long term durability providing therapeutic anticoa-
gulation can be achieved compared to a bioprosthetic
valve which is likely to degenerate over time [1,23,32,33].
Mechanical valves may therefore be preferred in younger
patients so as to avoid later re-operation. Nonetheless
this must be balanced against the inconvenience and risk
of anticoagulation in a younger patient who may wish to
become pregnant or to participate in recreational or em-
ployment activities that entail a greater risk of trauma.
The balancing of these factors means there is no univer-
sally correct approach to treatment choice in the indi-
vidual patient. Our data would suggest that mechanical
valves are preferred in younger patients irrespective of
whether they are Indigenous or not. This is particularly
the case when there is co-existent AF (and therefore an
additional indication for anticoagulation) and the patient
has represented following earlier PBV or past valve sur-
gery. Whilst such an approach can be argued as poten-
tially reasonable for patients living in remote Australia,
it would suggest that decisions regarding the use of
mechanical valves, particularly in younger Aboriginal
and Torres Strait Islander people should be undertakencautiously and in association with the patient, their
family, community and local health care providers. The
difficulty of maintaining long-term anticoagulation, par-
ticularly in a remote setting, should not be underesti-
mated. In a review of RHD patients prescribed warfarin,
37% had inadequate monitoring and 65% of INR results
were outside the recommended range [34]. Our findings
support an increasing preference for bioprosthetic over
mechanical valve replacement for mitral valve disease
and may reflect a greater appreciation of the factors out-
lined above. Variability in local management practices
including the timing of surgical referral and surgical
centre practices and expertise are also likely to influence
the timing and type of surgery performed. Earlier referral
to a surgical centre with a specific interest in valve repair
is thus likely to increase the possibility of repair.
Mitral valve repairs as a proportion of all mitral valve
procedures decreased (1.0% decrease/year, 95% CI −0.5 -
1.7) but this was not statistically significant. Mitral valve
repair compared to replacement has previously been as-
sociated with higher survival rates [35-37] in young
RHD patients, with Remenyi et al. [35] reporting actua-
rial survival at 10 and 14 years for patients with mitral
replacement of 79% and 44%, compared to 90% and 90%
for those who underwent mitral repair. Similarly Wang
et al. [37] in a systematic review of mitral valve repair
and replacement found a survival benefit associated with
mitral repair over replacement.
Not all valves, however, are suitable for repair [38] and
repaired valves have an increased risk of early reopera-
tion [38,39]. A key factor in increasing the chance of
successful mitral valve repair is likely to be earlier refer-
ral prior to the onset of valvular fibrosis and calcification
which may reduce the chance of successful repair [40]
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with greater experience in this area.
Whilst the proportion of mitral valve procedures that
were repairs rather than replacements had not signifi-
cantly altered over time it was noted that for all mitral
valve lesions, not just mitral regurgitation, that mitral
valve repair was more likely in Indigenous patients. This
is likely to reflect an understanding of the difficulties as-
sociated with anticoagulation. Non-Indigenous patients
are more likely to reside in metropolitan Australia and
to be more likely to be able to achieve safe anticoagulant
use and monitoring. In such a setting mechanical valve
replacement with attendant long-term anticoagulation is
likely to be preferable. The utilization of mitral valve re-
pair in mitral stenosis and mixed mitral valve disease
demonstrates the diversity of valvular lesions that are
encountered and dealt with by surgeons when dealing
with RHD and the broad scope of expertise required.
Limitations of the study
The main limitation of this study is that it is restricted to
Australian surgical practice and does not reflect manage-
ment in other countries. Nonetheless overall this sample
is likely to provide an accurate representation of surgical
management of RHD in Australia. Whilst the ANZSCTS
database receives data from 19 Australian public hospitals
there are six public hospitals in Australia which perform
cardiac surgery but do not provide data. It is unlikely the
inclusion of these centres would have significantly altered
our findings. Of particular note is the inclusion of data
from the major Australian centres performing RHD-
related valve surgery in Aboriginal Australian and Torres
Strait Islander patients. The multiple data collection sites
may have led to variable data coding. This was however
minimised by each site employing its own data manager
who was supported with training and standard data defini-
tions, the use of standardised data entry systems and cen-
tralised auditing of site-specific data.
Conclusions
This study is one of the largest reviews of patients
undergoing RHD valve surgery. Mitral and aortic valve
disease remains the focus of most surgery but tricuspid
valve procedures are not uncommon. A range of factors
have been identified which are associated with particular
surgical procedures. Whilst many of these reflect the
underlying nature of disease, the role of AF in predicting
treatment choice would suggest that earlier surgery,
prior to the onset of AF, and more aggressive manage-
ment of AF if it does occur, may allow a broader choice
of intervention and, correspondingly, less requirement
for life-long anticoagulation. Whilst mechanical valves
were more likely to be used in younger patients, this
needs to be balanced against fertility, lifestyle planningand the safety of anticoagulant use particularly in youn-
ger, remote and Aboriginal and Torres Strait Islander
patients. The greater use of bioprosthetic valves, valve
repair and PBV, whilst having a greater risk of reopera-
tion, may be more suitable in such patients. Earlier refer-
ral and surgical management of such patients to centres
with expertise in managing RHD valve disease is likely
to provide greater opportunity for valve repair and PBV.
Abbreviations
RHD: Rheumatic heart disease; AF: Atrial fibrillation; PBV: Percutaneous
balloon valvuloplasty; ANZSCTS: Australia and New Zealand Society of
Cardiac and Thoracic Surgeons; CABG: Coronary artery bypass grafting;
eGFR: Estimated glomerular filtration rate; MDRD: Modification of Diet in
Renal Disease; NYHA: New York Heart Association; LVEF: Left ventricular
ejection fraction; CI: Confidence interval; SD: Standard deviation;
IQR: Interquartile range; OR: Odds ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EAR performed the statistical analysis and drafted the manuscript. LT assisted
with acquisition of data and analysis. RAB and helped with revision of the
manuscript. JSB and helped with revision of the manuscript. AB conceived of
the study and participated in its design and coordination and helped helped
with revision of the manuscript. CMR assisted with acquisition of data and
helped helped with revision of the manuscript. RT helped helped with
revision of the manuscript. WW helped with revision of the manuscript. GPM
conceived of the study participated in the design of the study, assisted with
the statistical analysis and interpretation and helped to draft the manuscript.
All authors read and approved the final manuscript.
Acknowledgments
Anne Russell is supported by an NHMRC Postgraduate Scholarships Grant.
Graeme Maguire is supported by an NHMRC Practitioner Fellowship and the
Margaret Ross Chair in Indigenous Health. Christopher Reid is supported by
an NHMRC Senior Research Fellowship. Alex Brown is supported by a Viertel
Senior Medical Research Fellowship. Supported by NHMRC Centre for
Research Excellence to Reduce Inequality in Heart Disease.
Author details
1Baker IDI Central Australia, PO Box 1294, Alice Springs, NT 0811, Australia.
2School of Epidemiology and Preventive Medicine, Monash University,
Melbourne, Victoria, Australia. 3Department of Cardiac and Thoracic Surgery,
Flinders Medical Centre, Adelaide, SA, Australia. 4Department of Surgery,
School of Medicine, Flinders University, Adelaide, SA, Australia.
5Wardliparingga Aboriginal Research Unit, South Australia Health and
Medical Research Institute, Adelaide, SA, Australia. 6School of Population
Health, University of South Australia, Adelaide, SA, Australia. 7Department of
Cardiothoracic Surgery, The Townsville Hospital, Queensland, Australia.
8Cardiology Department, Prince of Wales Hospital, Randwick, NSW, Australia.
9School of Medicine, James Cook University, Cairns, Queensland, Australia.
Received: 2 August 2014 Accepted: 23 September 2014
Published: 2 October 2014
References
1. Carapetis J, Steer A, Mulholland E, Weber M: The global burden of group A
streptococcal diseases. Lancet Infect Dis 2005, 5:685–694.
2. Zühlke L, Watkins D, Engel ME: Incidence, prevalence and outcomes of
rheumatic heart disease in South Africa: a systematic review protocol.
BMJ Open 2014, 4:e004844. doi:10.1136/bmjopen-2014-004844.
3. Remenyi B, Carapetis J, Wyber R, Taubert K, Mayosi BM: Position statement
of the World Heart Federation on the prevention and control of
rheumatic heart disease. Nat Rev Cardiol 2013, 10:284–292.
4. RHDAustralia (ARF/RHD writing group), National Heart Foundation of
Australia and the Cardiac Society of Australia and New Zealand: Australian
guideline for prevention, diagnosis and management of acute rheumatic fever
Russell et al. BMC Cardiovascular Disorders 2014, 14:134 Page 12 of 12
http://www.biomedcentral.com/1471-2261/14/134and rheumatic heart disease. 2nd edition. Darwin: Menzies School of Health
Research; 2012.
5. Australian Institute of Health & Welfare 2013: Rheumatic heart disease and
acute rheumatic fever in Australia: 1996–2012. In Cardiovascular disease
series. Cat. no. CVD 60. Canbera: AIHW; 2013.
6. Remenyi B, Wilson N, Steer A, Ferreira B, Kado J, Kumar K, Lawrenson J,
Maguire G, Marijon E, Mirabel M, Mocumbi AO, Mota C, Paar J, Saxena A,
Scheel J, Stirling J, Viali S, Balekundri VI, Wheaton G, Zühlke L, Carapetis J:
World Heart Federation criteria for echocardiographic diagnosis of
rheumatic heart disease–an evidence-based guideline. Nature reviews
Cardiology 2012, 9:297–309.
7. Roberts K, Maguire G, Brown A, Atkinson D, Reményi B, Wheaton G, Kelly A,
Kumar RK, Su JY, Carapetis JR: Echocardiographic screening for rheumatic
heart disease in high and low risk Australian children. Circulation 2014,
129:1953–1961.
8. Lehman SJ, Baker RA, Aylward PE, Knight JL, Chew DP: Outcomes of
cardiac surgery in Indigenous Australians. Med J Aust 2009, 190:588–593.
9. Alizzi AM, Knight JL, Tully PJ: Surgical challenges in rheumatic heart
disease in the Australian indigenous population. Heart Lung Circ 2010,
19:295–298.
10. Maguire GP, Carapetis JR, Walsh WF, Brown AD: The future of acute
rheumatic fever and rheumatic heart disease in Australia. Med J Aust
2012, 197:133–134.
11. Enriquez-Sarano M, Akins CW, Vahanian A: Mitral regurgitation. Lancet
2009, 373:1382–1394.
12. Bhandari S, Subramanyam K, Trehan N: Valvular heart disease: diagnosis
and management. J Assoc Physicians India 2007, 55:575–584.
13. Baskerville CA, Hanrahan BB, Burke AJ, Holwell AJ, Remond MG, Maguire GP:
Infective endocarditis and rheumatic heart disease in the north of
Australia. Heart Lung Circ 2012, 21:36–41.
14. Zakkar M, Amirak E, Chan KMJ, Punjabi PP: Rheumatic Mitral Valve Disease:
Current Surgical Status. Prog Cardiovasc Dis 2009, 51:478–481.
15. ANZSCTS: National Cardiac Surgery Database Program, Standard Operating
Procedures Manual v1.1. Melbourne: CCRE, Monash University; 2012.
16. Australian Bureau of Statistics: Australian Statistical Geography Standard
(ASGS) Remoteness Areas classification 2011 - all of Australia. Canberra:
Australian Bureau of Statistics; 2013.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI,
Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to
estimate glomerular filtration rate. Ann Intern Med 2009, 150:604–612.
18. The Criteria Committee of the New York Heart Association: Nomenclature
and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th
edition. Boston Mass: Little, Brown & Co; 1994.
19. Year Book Australia [Internet]. http://www.abs.gov.au/ausstats/abs@.nsf. 2012
[cited 12 March 2014].
20. Bernal JM, Ponton A, Diaz B, Llorca J, Garcia I, Sarralde A, Diago C, Revuelta
JM: Surgery for rheumatic tricuspid valve disease: a 30-year experience.
J Thorac Cardiovasc Surg 2008, 136:476–481.
21. Choudhary SK, Talwar S, Dubey B, Chopra A, Saxena A, Kumar AS: Mitral
valve repair in a predominantly rheumatic population. Long-term results.
Tex Heart Inst J 2001, 28:8–15.
22. Wiemers P, Marney L, Muller R, Brandon M, Kuchu P, Kuhlar K, Uchime C,
Kang D, White N, Greenup R, Fraser JF, Yadav S, Tam R: Cardiac surgery in
Indigenous Australians–how wide is 'the gap'? Heart Lung Circ 2014,
23:265–272.
23. Essop MR, Nkomo VT: Rheumatic and Nonrheumatic Valvular Heart
Disease: Epidemiology, Management, and Prevention in Africa.
Circulation 2005, 112:3584–3591.
24. Wang A, Krasuski R, Warner J, Pieper K, Kisslo K, Bashore T, Harrison JK: Serial
echocardiographic evaluation of restenosis after successful percutaneous
mitral commissurotomy. J Am Coll Cardiol 2002, 39:328–334.
25. Ben-Farhat M, Betbout F, Gamra H, Maatouk F, Ben-Hamda K, Abdellaoui M,
Hammami S, Jarrar M, Addad F, Dridi Z: Predictors of long-term event-free
survival and of freedom from restenosis after percutaneous balloon
mitral commissurotomy. Am Heart J 2001, 142:1072–1079.
26. Fawzy ME, Fadel B, Al-Sergani H, Al Amri M, Hassan W, Abdulbaki K, Shoukri
M, Canver C: Long-Term Results (Up to 16.5 Years) of Mitral Balloon
Valvuloplasty in a Series of 518 Patients and Predictors of Long-Term
Outcome. J Interv Cardiol 2007, 20:66–72.27. Fawzy ME, Shoukri M, Hassan W, Nambiar V, Stefadouros M, Canver CC: The
impact of mitral valve morphology on the long-term outcome of mitral
balloon valvuloplasty. Catheter Cardiovasc Interv 2007, 69:40–46.
28. Gamra H, Betbout F, Ben Hamda K, Addad F, Maatouk F, Dridi Z, Hammami
S, Abdellaoui M, Boughanmi H, Hendiri T, Ben Farhat M: Balloon mitral
commissurotomy in juvenile rheumatic mitral stenosis: a ten-year clinical
and echocardiographic actuarial results. Eur Heart J 2003, 24:1349–1356.
29. Cass A, Cunningham J, Wang Z, Hoy W: Regional variation in the
incidence of end-stage renal disease in Indigenous Australians. Med J
Aust 2001, 175:24–27.
30. Prabhu A, Tully PJ, Tuble S, Bennetts J, Baker RA: Morbidity and Morality
Outcomes of Aboriginal and Torres Strait Islander Peoples After Isolated
Cornary Artery Bypass Graft Surgery [abstract]. Heart Lung Circ 2011,
20:792.
31. Blaustein AS, Ramanathan A: Tricuspid valve disease. Clinical evaluation,
physiopathology, and management. Cardiol Clin 1998, 16:551–572.
32. Edwin F, Aniteye E, Tettey M, Tamatey M, Frimpong-Boateng K: Outcome
of left heart mechanical valve replacement in West African children - A
15-year retrospective study. J Cardiothorac Surg 2011, 6:57.
33. Yau TM, El-Ghoneimi YA, Armstrong S, Ivanov J, David TE: Mitral valve
repair and replacement for rheumatic disease. J Thorac Cardiovasc Surg
2000, 119:53–60.
34. Rémond MGW, Severin KL, Hodder Y, Martin J, Nelson C, Atkinson D,
Maguire GP: Variability in disease burden and management of rheumatic
fever and rheumatic heart disease in two regions of tropical Australia.
Intern Med J 2013, 43:386–393.
35. Remenyi B, Webb R, Gentles T, Russell P, Finucane K, Lee M, Wilson N:
Improved Long-Term Survival for Rheumatic Mitral Valve Repair
Compared to Replacement in the Young. World Journal for Pediatric and
Congenital Heart Surgery 2013, 4:155–164.
36. De Santo LS, Romano G, Della Corte A, Tizzano F, Petraio A, Amarelli C,
De Feo M, Dialetto G, Scardone M, Cotrufo M: Mitral mechanical replacement
in young rheumatic women: analysis of long-term survival, valve-related
complications, and pregnancy outcomes over a 3707-patient-year
follow-up. J Thorac Cardiovasc Surg 2005, 130:13–19.
37. Wang Z, Zhou C, Gu H, Zheng Z, Hu S: Mitral valve repair versus
replacement in patients with rheumatic heart disease. J Heart Valve Dis
2013, 22:333–339.
38. Bakir I, Onan B, Onan IS, Gul M, Uslu N: Is rheumatic mitral valve repair still
a feasible alternative?: indications, technique, and results. Tex Heart Inst J
2013, 40:163–169.
39. Sarralde J, Bernal J, Llorca J, Ponton A, Diez-Solorzano L, Gimenez-Rico JR,
Revuelta JM: Repair of rheumatic tricuspid valve disease: predictors of
very long-term mortality and reoperation. Ann Thorac Surg 2010,
90:503–508.
40. Chaudhry F, Upadya S, Singh V, Cusik D, Izrailtyan I, Sanders J, Hargrove C:
Identifying patients with degenerative mitral regurgitation for mitral
valve repair and replacement: a transesophageal echocardiographic
study. J Am Soc Echocardiogr 2004, 17:988–994.
doi:10.1186/1471-2261-14-134
Cite this article as: Russell et al.: A review of valve surgery for rheumatic
heart disease in Australia. BMC Cardiovascular Disorders 2014 14:134.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
